Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies

酒精使用障碍和大麻：测试新的减害策略

• 批准号: 10384999
• 负责人: KENT E. HUTCHISON
• 金额: $ 54万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-20 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10384999
• 关键词: Address; Alcohol consumption; Alcohols; Antiinflammatory Effect; Anxiety; Biological Markers; Canada; Cannabidiol; Cannabinoids; Cannabis; Consumption; Cues; Data; Disease; District of Columbia; Drug usage; Grant; Harm Reduction; Health Personnel; Hemp; Individual; Inflammation; Inflammatory; Instruction; Intervention; Laboratories; Legal; Literature; Mediating; Medical Marijuana; Mexico; North America; Outcome; Participant; Patients; Persons; Pharmaceutical Preparations; Pharmacology; Population; Prevalence; Public Health; Publishing; Randomized; Research; Research Support; Sales; Sampling; Symptoms; Testing; United States; Woman; Work; alcohol craving; alcohol cue; alcohol use disorder; comorbidity; cost; craving; drinking; improved; intervention effect; marijuana legalization; marijuana use; marijuana use disorder; marijuana user; men; novel; socioeconomics; systemic inflammatory response; treatment program; trend

Research Summary The prevalence of alcohol use disorders (AUDs) in the U.S. is approximately 12.7% and has shown a marked increase in recent years (Grant et al., 2017). Individuals with AUD often use cannabis, which may impact attempts to reduce or quit drinking. In the last six years, the United States has witnessed enormous changes concerning the public acceptance and availability of cannabis. Considering that cannabis has historically been the drug most often used by individuals with an AUD and considering the skyrocketing increase in availability of cannabis products, it is imperative for health care providers to understand how best to approach cannabis use with individuals who have an AUD and who want treatment. The central premise of the proposed research is that products with low THC and high CBD may be less harmful to AUD individuals who want to quit drinking, as compared to products with high THC only. It is hypothesized that individuals who switch from a high THC product to a low THC and higher CBD product will demonstrate superior outcomes compared to those individuals who do not switch. If the hypotheses are supported, the dissemination of the research would have an immediate effect on public health impact by educating patients and treatment providers about how to address the use of cannabis among individuals who want to quit or reduce alcohol consumption. To that end, individuals who currently use a high THC product and want to reduce or quit drinking will be randomly assigned to either the control condition (continue to use your current cannabis product as you wish) or the intervention condition (instruction to switch to low THC/high CBD product). Participants in the intervention condition choose the product and use as little or as much as they want during the study. Participants will be tested in the Mobile Pharmacology Laboratory at 6 and 12 week timepoints to determine the impact of these products on cue-elicited anxiety, cue-elicited alcohol craving, drinking outcomes, and biological markers of systemic inflammation.

研究综述 美国酒精使用障碍（AUD）的患病率约为12.7%， 近年来增加（Grant等人，2017年）。AUD患者经常使用大麻，这可能会影响 试图减少或戒酒。在过去的六年里，美国发生了巨大的变化， 关于公众对大麻的接受程度和供应情况。考虑到大麻在历史上 最常被AUD患者使用的药物，并考虑到 大麻产品，卫生保健提供者必须了解如何最好地处理大麻的使用 与那些患有澳大利亚元并希望接受治疗的人。拟议研究的中心前提是， 具有低THC和高CBD的产品可能对想要戒酒的AUD个体危害较小， 与仅具有高THC的产品相比。据推测，从高THC产品转换的个人 低THC和高CBD产品将证明上级结果相比，那些人， 不要切换。如果这些假设得到支持，研究的传播将立即产生影响。 通过教育患者和治疗提供者如何解决使用 大麻在想要戒烟或减少酒精消费的人中。为此， 目前使用高THC产品，并希望减少或戒烟将被随机分配到任何一个 控制条件（如您所愿继续使用您目前的大麻产品）或干预条件 （指示切换到低THC/高CBD产品）。参与者在干预条件下选择 产品和使用尽可能少或尽可能多，因为他们想要在研究期间。参与者将在移动的 在第6周和第12周时间点的药理学实验室，以确定这些产品对线索诱导的 焦虑、线索引发的酒精渴望、饮酒结果和全身炎症的生物标志物。